SAN DIEGO / May 09, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:
Citizens JMP Life Sciences Conference
Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY
2024 RBC Capital Markets Global Healthcare Conference
Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY
BofA Securities Health Care Conference
Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in Las Vegas, NV
Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.
Last Trade: | US$20.06 |
Daily Change: | -0.57 -2.76 |
Daily Volume: | 2,036,076 |
Market Cap: | US$3.380B |
September 24, 2025 August 25, 2025 August 06, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load